1. Home
  2. INLX vs IGC Comparison

INLX vs IGC Comparison

Compare INLX & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INLX
  • IGC
  • Stock Information
  • Founded
  • INLX 1996
  • IGC 2005
  • Country
  • INLX United States
  • IGC United States
  • Employees
  • INLX N/A
  • IGC N/A
  • Industry
  • INLX EDP Services
  • IGC Biotechnology: Pharmaceutical Preparations
  • Sector
  • INLX Technology
  • IGC Health Care
  • Exchange
  • INLX Nasdaq
  • IGC Nasdaq
  • Market Cap
  • INLX 40.8M
  • IGC 39.8M
  • IPO Year
  • INLX N/A
  • IGC N/A
  • Fundamental
  • Price
  • INLX $11.00
  • IGC $0.41
  • Analyst Decision
  • INLX
  • IGC Strong Buy
  • Analyst Count
  • INLX 0
  • IGC 2
  • Target Price
  • INLX N/A
  • IGC $4.00
  • AVG Volume (30 Days)
  • INLX 6.6K
  • IGC 667.7K
  • Earning Date
  • INLX 11-12-2025
  • IGC 11-11-2025
  • Dividend Yield
  • INLX N/A
  • IGC N/A
  • EPS Growth
  • INLX N/A
  • IGC N/A
  • EPS
  • INLX N/A
  • IGC N/A
  • Revenue
  • INLX $17,127,854.00
  • IGC $1,327,000.00
  • Revenue This Year
  • INLX N/A
  • IGC $15.26
  • Revenue Next Year
  • INLX $14.19
  • IGC $3.41
  • P/E Ratio
  • INLX N/A
  • IGC N/A
  • Revenue Growth
  • INLX N/A
  • IGC 24.95
  • 52 Week Low
  • INLX $8.74
  • IGC $0.25
  • 52 Week High
  • INLX $16.50
  • IGC $0.50
  • Technical
  • Relative Strength Index (RSI)
  • INLX 43.78
  • IGC 50.95
  • Support Level
  • INLX $11.11
  • IGC $0.39
  • Resistance Level
  • INLX $11.55
  • IGC $0.43
  • Average True Range (ATR)
  • INLX 0.12
  • IGC 0.02
  • MACD
  • INLX -0.08
  • IGC -0.00
  • Stochastic Oscillator
  • INLX 21.28
  • IGC 37.17

About INLX Intellinetics Inc.

Intellinetics Inc is a document service and solutions software company serving both the small-to-medium business and governmental sectors. The company's digital transformation products and services are provided through two reporting segments: Document Management and Document Conversion. The Document Management segment consists of solutions involving software platforms, which allow customers to capture and manage all documents across operations such as scanned hard-copy documents and all digital documents including those from Microsoft Office 365, digital images, audio, video, and emails. The company's Document Conversion offerings aid clients as a part of their overall document to convert documents from one medium to another. Majority of revenue is from Document Conversion Segment.

About IGC IGC Pharma Inc.

IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.

Share on Social Networks: